secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018810
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon reports Q1 net loss $38.7M; pipeline milestones expected through 2024
-----------------------------------------------------------------------------

- Net loss $38.7M ($0.52/sh) vs $35.4M ($0.92/sh) in Q1 2022; R&D spend rose to $32.3M.
- Cash and investments $228.2M; runway into 2025 for ongoing trials.
- Phase 2 ARCHER trial of ANX007 in geographic atrophy data expected mid-2023.
- Phase 3 GBS trial enrollment completion 2H'23; topline results 1H'24.
- Initial Phase 1b data for ANX009 in lupus nephritis due 1H'23; ANX1502 oral data 2H'23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017023018810/0000950170-23-018810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017023018810/annx-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer